Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In this single-institute pilot study, 30 subjects with hepatocellular cancer were randomized to transarterial chemoembolization with or without bevacizumab. Bevacizumab use significantly improved progression-free survival at 16 weeks but no significant difference was seen with respect to the primary outcome (vessel count) or in the overall survival.

Transarterial Chemoembolization ± Intravenous Bevacizumab in the Treatment of Hepatocellular Cancer